跳至主要内容
临床试验/ACTRN12622000428763
ACTRN12622000428763尚未招募未知

Circulatory effects of peripheral chemoreflex inhibition at rest and exercise in hypertension

niversity of Auckland0 个研究点目标入组 50 人开始时间: 2022年3月16日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Diagnosis
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Participants with essential hypertension (At least Stage 2 hypertension; untreated office SBP > 140 mmHg or DBP > 90 mmHg)
  • - Normotensive controls (office SBP < 120 mmHg and DBP < 80 mmHg)
  • - Men and women
  • - Aged over 18 years
  • - Body mass index < 35 kg/m2

排除标准

  • - Significant arrhythmias (e.g., atrial fibrillation, previous VT / significant ventricular ectopy)
  • - Significant valvular heart disease
  • - Previous coronary artery bypass surgery
  • - Primary angioplasty for acute ST elevation
  • - Myocardial infarction
  • - Severe left ventricular dysfunction
  • - Recent (< 3 months) ischemic stroke
  • - Current smoker
  • - Body mass index < 18 kg·m2
  • - Current pregnancy
  • - Users of recreational drugs
  • - Abusers of alcohol
  • - Inability to fully or appropriately provide consent (e.g., language issue, reading capability)
  • - Underlying medical conditions, which in the opinion of the Investigator place the participant at unacceptably high risk for participating in the study

研究者

发起方
niversity of Auckland

相似试验